362 related articles for article (PubMed ID: 16258654)
21. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Hadden RD; Cornblath DR; Hughes RA; Zielasek J; Hartung HP; Toyka KV; Swan AV
Ann Neurol; 1998 Nov; 44(5):780-8. PubMed ID: 9818934
[TBL] [Abstract][Full Text] [Related]
22. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
Tada M; Tada M; Ishiguro H; Yagi E; Hirota K
No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881
[TBL] [Abstract][Full Text] [Related]
23. Neuromuscular respiratory failure in Guillain-Barre Syndrome: evaluation of clinical and electrodiagnostic predictors.
Sundar U; Abraham E; Gharat A; Yeolekar ME; Trivedi T; Dwivedi N
J Assoc Physicians India; 2005 Sep; 53():764-8. PubMed ID: 16334619
[TBL] [Abstract][Full Text] [Related]
24. CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome.
Petzold A; Hinds N; Murray NM; Hirsch NP; Grant D; Keir G; Thompson EJ; Reilly MM
Neurology; 2006 Sep; 67(6):1071-3. PubMed ID: 17000982
[TBL] [Abstract][Full Text] [Related]
25. [Clinical features of Guillain-Barré syndrome in 41 patients admitted to a public hospital].
Cea G; Jara P; Quevedo F
Rev Med Chil; 2015 Feb; 143(2):183-9. PubMed ID: 25860360
[TBL] [Abstract][Full Text] [Related]
26. [Intravenous immunoglobulin therapy for Guillain-Barré syndrome in Japan: changes in treatment after its inclusion in health insurance coverage].
Nishimoto Y; Yuki N
Rinsho Shinkeigaku; 2004 Sep; 44(9):633-5. PubMed ID: 15515710
[TBL] [Abstract][Full Text] [Related]
27. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
Korinthenberg R; Schessl J; Kirschner J; Mönting JS
Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024
[TBL] [Abstract][Full Text] [Related]
28. [Guillain-Barre syndrome in the paediatric age: epidemiological, clinical and therapeutic profile in a hospital in El Salvador].
Ramírez-Zamora M; Burgos-Ganuza CR; Alas-Valle DA; Vergara-Galán PE; Ortez-González CI
Rev Neurol; 2009 Mar 16-31; 48(6):292-6. PubMed ID: 19291652
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
[TBL] [Abstract][Full Text] [Related]
30. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome.
Odaka M; Yuki N; Hirata K
J Neurol; 2003 Aug; 250(8):913-6. PubMed ID: 12928908
[TBL] [Abstract][Full Text] [Related]
31. Hospital admissions for Guillain-Barré syndrome in the United States, 1993-2004.
Frenzen PD
Neuroepidemiology; 2007; 29(1-2):83-8. PubMed ID: 17925599
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic Factors in Guillain-Barré Syndrome].
Kaida K
Brain Nerve; 2015 Nov; 67(11):1411-9. PubMed ID: 26560956
[TBL] [Abstract][Full Text] [Related]
33. [Guillain-Barre syndrome. Experience in a third level hospital].
Téllez-Zenteno JF; Jacinto-Tinajero JC; Avila-Funes A; García-Ramos G; Negrete-Pulido O; Sentíes-Madrid H
Rev Invest Clin; 2001; 53(4):311-4. PubMed ID: 11599477
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Guillain-Barré syndrome and CIDP.
van Doorn PA
J Peripher Nerv Syst; 2005 Jun; 10(2):113-27. PubMed ID: 15958124
[TBL] [Abstract][Full Text] [Related]
35. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
Shahrizaila N; Yuki N
Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
[TBL] [Abstract][Full Text] [Related]
36. [Epidemiological characteristics of Guillain-Barré syndrome in urban and rural areas in Beijing and Hebei, China].
Hong X; Zhang Z; Wang J; Zhang B; Yin W; Zhang X; Tang X; Guo Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Apr; 22(2):115-9. PubMed ID: 12903510
[TBL] [Abstract][Full Text] [Related]
37. Effect of human immunodeficiency virus on intensive care unit outcome of patients with Guillain-Barré syndrome.
Schleicher GK; Black A; Mochan A; Richards GA
Crit Care Med; 2003 Jun; 31(6):1848-50. PubMed ID: 12794429
[TBL] [Abstract][Full Text] [Related]
38. Clinical features and outcome of Guillain-Barre syndrome in Saudi Arabia: a multicenter, retrospective study.
Alanazy MH; Bakry SS; Alqahtani A; AlAkeel NS; Alazwary N; Osman AM; Mustafa RA; Al-Harbi TM; Abdulmana SO; Amper AC; Aldughaythir Y; Ali AS; Makkawi S; Maglan A; Alamoudi L; Alsulaiman F; Alabdali M; AlShareef AA; Abuzinadah AR; Bamaga AK
BMC Neurol; 2021 Jul; 21(1):275. PubMed ID: 34253174
[TBL] [Abstract][Full Text] [Related]
39. [Plasmapheresis in Guillain-Barre syndrome].
Carbajal-Ramírez A; Castañón-González JA; Osvaldo-Talavera J; de la Torre-Nieto ML; León-Gutiérrez MA
Gac Med Mex; 2002; 138(6):527-31. PubMed ID: 12532617
[TBL] [Abstract][Full Text] [Related]
40. Evolving pattern of Guillain-Barre syndrome in a community hospital in Israel.
Kushnir M; Klein C; Pollak L; Rabey JM
Acta Neurol Scand; 2008 May; 117(5):347-50. PubMed ID: 17995988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
